Year in Aesthetics — 2026

AbbVie's Allergan Aesthetics made three material pricing and rebate moves in 2026 (April, May, and June), signaling aggressive defense of its Botox and Juvéderm duopoly. Simultaneously, Evolus filed multiple material events around Jeuveau and its Evolus Rewards program, explicitly targeting medspas with lower price points. The message was clear: loyalty programs and volume discounts are now table stakes. For owners, this means margin compression on core injectables is structural, not cyclical. The Allē ecosystem—bundling Botox, Juvéderm, and loyalty incentives—is designed to lock in patient wallets and reduce switching. Practices that relied on high-margin injectable revenue must now diversify into complementary services (body contouring, skin treatments, wellness) or accept lower per-unit profitability. The days of 60%+ margins on neuromodulators are over.

The FDA approved Restylane Contour for temple hollowing and RHA Dynamic Volume for midface augmentation and age-related volume loss. Skinvive by Juvéderm also won approval for neck wrinkles. These are meaningful but incremental wins—they expand the addressable market for fillers in specific anatomical zones, but they don't fundamentally change the category. For practices, the takeaway is straightforward: train staff on these new indications, update consent forms, and market them to existing patients. Temple and midface treatments are higher-ticket items than lips or cheeks, so they can help offset margin pressure on core injectables. However, these indications are not blockbuster drivers; they're table-stakes for practices that want to stay current and competitive.

Medical aesthetics industry leaders confirmed in 2026 that "semaglutide face"—facial fat loss and volume depletion caused by GLP-1 weight-loss drugs like Novo Nordisk's semaglutide—is a real and growing side effect. This has created a new patient cohort: people losing weight rapidly and seeking facial volume restoration, skin tightening, and body contouring. The opportunity is genuine—these patients are motivated, often affluent, and willing to spend. But the complexity is real too. Practices must educate patients on realistic outcomes, manage expectations around timing (volume loss may continue as weight loss continues), and coordinate with their prescribing physicians. Additionally, GLP-1 patients may be candidates for energy-based devices (RF, microneedling, laser) to address skin laxity, not just fillers. Owners who build expertise in this patient segment—combining injectables, devices, and skin treatments—can capture significant revenue.

Allergan Aesthetics won Health Canada approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration neuromodulator for glabellar lines. This is a meaningful product innovation—faster onset and shorter duration than traditional Botox—but it's available in Canada, not yet the U.S. FDA. For U.S. practice owners, Boey remains on the roadmap but not yet a revenue driver. However, the approval signals that the neuromodulator category is still evolving and that speed-of-onset is becoming a competitive differentiator. Practices should monitor the U.S. regulatory timeline and prepare to educate patients on the differences between traditional and rapid-onset products once Boey (or similar competitors) reach the U.S. market. Regulatory fragmentation—approvals in Canada or EU before the U.S.—will likely continue, creating opportunities for practices in border regions or those with international patient bases.

InMode received an unsolicited acquisition proposal in June 2026 at $16.20 per share from a CEO-linked buyout group. While the deal status remained uncertain at year-end, the proposal underscored broader M&A momentum in the device sector. Energy-based device companies (RF, laser, microneedling platforms) are consolidating as larger players seek scale and practices demand integrated, multi-modality solutions. For owners, this means: (1) device vendors may change ownership or strategy; (2) service and support may shift; (3) pricing and lease terms may become more aggressive. Practices should diversify device portfolios to avoid over-reliance on any single vendor and should negotiate multi-year service agreements now, before consolidation reshapes the vendor landscape.

A former Port St. Lucie medspa owner received a 45-year sentence for botched cosmetic surgery, and enforcement actions against unlicensed injectors and practitioners continued throughout 2026. While high-profile criminal cases are rare, they underscore the regulatory and liability risks of operating outside compliance. Additionally, GLP-1 compounding and supply-chain rules are evolving, creating new compliance burdens for practices that offer these services. For owners, the lesson is clear: invest in staff licensing and credentialing, maintain rigorous consent and safety protocols, and stay current on state and federal regulations around injectables, devices, and compounded medications. Compliance is not a cost center—it's an insurance policy against catastrophic liability.

Looking ahead, expect continued M&A in devices and injectables as larger players consolidate market share. Pricing pressure on core injectables will persist, forcing practices to compete on service quality, patient experience, and complementary offerings rather than price alone. GLP-1 demand will remain a tailwind for body contouring and facial volume restoration, but practices must build expertise and infrastructure to capture this segment effectively. Regulatory scrutiny will intensify, particularly around compounding and unlicensed practice. For independent owners, the path forward is clear: diversify revenue streams, invest in staff and compliance, build expertise in high-margin services (body contouring, advanced skin treatments, GLP-1 patient management), and ruthlessly manage costs. The era of high-margin injectable-only practices is over.